Kenna Anderes Selected Research

Tyrosine Kinase Inhibitors

9/2012

Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kenna Anderes Research Topics

Disease

19	Neoplasms (Cancer) 01/2016 - 01/2008
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2023 - 09/2012
2	Lung Neoplasms (Lung Cancer) 01/2023 - 01/2016
2	Breast Neoplasms (Breast Cancer) 01/2016 - 11/2007
2	Circulating Neoplastic Cells 01/2016 - 07/2014
2	Ovarian Neoplasms (Ovarian Cancer) 01/2016 - 04/2012
2	Hypoxia (Hypoxemia) 04/2012 - 12/2010
1	Colorectal Neoplasms (Colorectal Cancer) 04/2024
1	Adenocarcinoma 01/2016
1	Hemorrhage 07/2014
1	Hypertension (High Blood Pressure) 07/2014
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 09/2012
1	Hematologic Neoplasms (Hematological Malignancy) 07/2012
1	Leukemia 07/2012
1	Lymphoma (Lymphomas) 07/2012
1	Inflammation (Inflammations) 11/2011
1	Neoplasm Metastasis (Metastasis) 11/2011
1	Inflammatory Breast Neoplasms 11/2011
1	Rheumatoid Arthritis 11/2011
1	Prostatic Neoplasms (Prostate Cancer) 10/2011
1	Pain (Aches) 03/2011
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 10/2009
1	Carcinoid Tumor (Carcinoid) 10/2009
1	Carcinogenesis 10/2009
1	Ataxia Telangiectasia (Louis Bar Syndrome) 07/2009
1	Skin Neoplasms (Skin Cancer) 07/2009
1	Disease Progression 01/2009
1	Hyperglycemia 12/2002

Drug/Important Bio-Agent (IBA)

6	silmitasertibIBA 09/2012 - 12/2010
5	Casein Kinase II (Casein Kinase 2)IBA 09/2012 - 01/2011
4	Carboxylic AcidsIBA 07/2012 - 01/2011
3	adagrasibIBA 04/2024 - 01/2022
3	Ribosomal DNA (rDNA)IBA 07/2012 - 10/2009
3	RNA Polymerase I (Polymerase I, RNA)IBA 07/2012 - 02/2011
3	CX 5461IBA 07/2012 - 02/2011
2	Bevacizumab (Avastin)FDA Link 07/2014 - 01/2009
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/2014 - 01/2008
2	ErbB Receptors (EGF Receptor)IBA 09/2012 - 04/2012
2	Gemcitabine FDA Link 04/2012 - 11/2007
2	Interleukin-6 (Interleukin 6)IBA 04/2012 - 11/2011
2	Phosphotransferases (Kinase)IBA 10/2011 - 10/2009
2	Proteins (Proteins, Gene)FDA Link 10/2011 - 10/2009
2	Docetaxel (Taxotere)FDA Link 07/2009 - 01/2009
1	Cetuximab (Erbitux)FDA Link 04/2024
1	B7-H1 AntigenIBA 01/2022
1	PlatinumIBA 01/2022
1	Folate Receptor 1IBA 01/2016
1	AntibodiesIBA 01/2016
1	cediranib (AZD2171)IBA 07/2014
1	NitratesIBA 07/2014
1	Nitric Oxide Synthase (NO Synthase)IBA 07/2014
1	OxidesIBA 07/2014
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 09/2012
1	Tyrosine Kinase InhibitorsIBA 09/2012
1	benzo(c)fluoreneIBA 07/2012
1	RNA (Ribonucleic Acid)IBA 07/2012
1	EnzymesIBA 07/2012
1	Drug CombinationsIBA 04/2012
1	Cisplatin (Platino)FDA LinkGeneric 04/2012
1	proto-oncogene proteins pimIBA 02/2012
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 11/2011
1	CytokinesIBA 11/2011
1	Formaldehyde (Formol)FDA Link 03/2011
1	DNA-Directed RNA Polymerases (RNA Polymerase)IBA 02/2011
1	Ribosomal RNAIBA 02/2011
1	Adenosine Triphosphate (ATP)IBA 01/2011
1	Monoclonal AntibodiesIBA 11/2010
1	Cadherins (E-Cadherin)IBA 11/2010
1	PF-03732010 monoclonal antibodyIBA 11/2010
1	Membrane Glycoproteins (Membrane Glycoprotein)IBA 11/2010
1	CX 3543IBA 10/2009
1	NucleolinIBA 10/2009
1	PF 00477736IBA 07/2009
1	Caffeine (No Doz)FDA LinkGeneric 07/2009
1	Cyclic AMP (AMP, Cyclic)IBA 07/2009
1	Small Interfering RNA (siRNA)IBA 07/2009
1	Capsules (Microcapsules)IBA 01/2009
1	Antineoplastic Agents (Antineoplastics)IBA 01/2009
1	palbociclibIBA 01/2009
1	DNA (Deoxyribonucleic Acid)IBA 08/2008
1	Glucagon (Glukagon)FDA Link 12/2002

Therapy/Procedure

8	Therapeutics 01/2022 - 08/2008
1	Drug Therapy (Chemotherapy) 01/2022
1	Lasers (Laser) 01/2016